期刊文献+

CD_(44)V_6基因在前列腺癌组织中的表达及其意义

Expression and significance of CD_(44)V_6 gene in prostate cancer tissue
下载PDF
导出
摘要 目的 探讨CD4 4V6 基因与前列腺癌 (PCa)的发生、转移及预后的关系。方法 采用S P免疫组织化学方法检测 82例PCa组织中CD4 4V6 基因的表达情况。结果 CD4 4V6 基因在前列腺癌中有较高的表达 ,阳性率为 46 3 % (38/82 ) ,其中伴盆腔淋巴结转移或骨转移者阳性率为62 5 % (1 5/2 4 ) ,无转移者阳性率 37 9% (2 3/58) ,两者具有显著性差异 (P <0 0 1 )。CD4 4V6 在PCa组织中的高表达还与癌组织的Gleason评分及预后有关 (P <0 0 5)。结论 具有CD4 4V6 高表达的PCa具有更强的浸润和转移能力 ,恶性度较高 ,分化较差 ,CD4 4V6 可作为判断预后及指导术后治疗的一项重要指标。 Objective To study the relationship between CD 44 V 6 expression in prostate cancer tissue and metastasis and prognosis.Methods The expression of CD 44 V 6 gene was detected in 82 cases of prostate cancer with S-P immunohistochemical method. Results The positive rate of CD 44 V 6 expression in prostate cancer tissue was 46.3% (38/82). Among them, the positive rate was 62.5% (15/24) in the prostate cancer patients with lymph node or bone metastasis, was 37.9 (23/58) in patients without metastasis, and the difference in the two situation was significant (P<0.01). The expression of CD 44 V 6 was correlated with the core of Gleason and prognosis of prostate cancer. Conclusions The CD 44 V 6 over-expression promoted the invasion and metastasis of prostate carcinomas. CD 44 V 6 expression was valuable to evaluate the prognosis and guide clinical treatment of prostate cancer.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2004年第10期928-930,共3页 Chinese Journal of Gerontology
关键词 CD44V6基因 前列腺癌 高表达 阳性率 预后 癌组织中 转移 结论 指导 能力 Prostate carcinoma tissue CD 44 V6 gene Metastasis and prognosis
  • 相关文献

参考文献13

  • 1Brooks L, Niedobitek G, Agathangelou A, et al.The expression of variant CD44 in nasopharyngeal carcinoma is unrelated to expression of LMP-1[J]. Am J Pathol, 2001;141(4):102.
  • 2Screaton GR, Bell MV. Genomic structure of DNA encoding the lymphcyte homing receptor CD44 reveals at least 12 alternatively spliced exons [J]. Proc Natl Acad Sci USA, 1999;28(12):1260.
  • 3Emark G, Jennings T, Robinson L , et al.Restricted pattern of CD44 variant exon expression in human papillay thyroid carcinoma [J]. Cancer Res, 1998;56(5):1037-41.
  • 4Guntheret U, Hofman M, Rudy W, et al.A new variant of glycoprotein CD44 confers metastatic to rat carcinoma cells [J]. Cell,1991;65(1):12-6.
  • 5Koretz K, Moller P, Lehner T, et al.Effect of CD44V6 on survial in colorectal carcinoma [J]. Cancer, 1999;345(2):327-8.
  • 6Joensun H, Klenip J, Toikkanes, et al.Glycoprotein CD44 expression and its association with survival in breast cancer [J]. Am Pathol, 1999;143(3):867-90.
  • 7Uhl-steidl M , Muller-Holzner E, Zeimet AG, et al.Prognositic value of CD44 splice variant expression in ovarian cancer[J].Oncology,1995;52(5):400-4.
  • 8Ristamkir, Anssun H, Oresoderstrom K, et al.CD44V6 expression in non-Hordykins lymphoma [J].Pathology, 1995;176(2):259-63.
  • 9Harm HJ, Holi, Chang JY, et al.Significance of CD44 gene products for prostate cancer diagnosis and disease evaluation [J].Cancer,2002;340(8827):1053.
  • 10周英琼,曾思恩,李凡彩,陈锋.CD44V6蛋白在鼻咽癌组织中的表达[J].实用癌症杂志,2002,17(3):274-276. 被引量:3

二级参考文献20

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部